Literature DB >> 8680544

Serum hyaluronate in patients with acute and fulminant hepatitis.

K Suzuki1, R Endo, Y Takikawa, I Nakadate, S Sato.   

Abstract

We evaluated serum hyaluronate (HA) levels in 17 patients with acute hepatitis and 9 with fulminant hepatitis (FH). Upon admission, patients with FH showed increased levels of serum HA and these levels showed significant correlation with biochemical parameters such as human hepatocyte growth factor, hepaplastin test, and prothrombin activity. In patients with AH, the levels of serum HA decreased during convalescence. Higher serum HA levels were observed in patients with type A acute hepatitis than in patients with non-A type. In patients with FH, serum HA levels were decreased in the survivors, while they were elevated in the non-survivors. These findings suggest that serum HA levels may be a useful indicator for evaluating the prognosis of patients with acute and fulminant hepatitis. Further study is necessary to determine whether there is a causal relationship between elevated serum HA levels and the type of hepatitis virus.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8680544     DOI: 10.1007/bf02389523

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  29 in total

1.  Hyaluronic acid in the assessment of liver graft function.

Authors:  S G Pollard; M A Forbes; S M Metcalfe; E H Cooper; R Y Calne
Journal:  Transplant Proc       Date:  1990-10       Impact factor: 1.066

2.  Endothelial cell transformation in primary biliary cirrhosis: a morphological and biochemical study.

Authors:  C Babbs; N Y Haboubi; J M Mellor; A Smith; B P Rowan; T W Warnes
Journal:  Hepatology       Date:  1990-05       Impact factor: 17.425

3.  Serum hyaluronate in primary biliary cirrhosis--a biochemical marker for progressive liver damage.

Authors:  A Nyberg; A Engström-Laurent; L Lööf
Journal:  Hepatology       Date:  1988 Jan-Feb       Impact factor: 17.425

4.  Tumour necrosis factor production in fulminant hepatic failure: relation to aetiology and superimposed microbial infection.

Authors:  M de la Mata; A Meager; N Rolando; H M Daniels; K T Nouri-Aria; A K Goka; A L Eddleston; G J Alexander; R Williams
Journal:  Clin Exp Immunol       Date:  1990-12       Impact factor: 4.330

5.  Usefulness of antithrombin III and alpha 2-plasmin inhibitor in early differentiation of fulminant hepatitis and severe form of acute hepatitis.

Authors:  S Sato; A Murakami; T Yoshida; T Kashiwabara; K Suzuki; I Kaito
Journal:  Gastroenterol Jpn       Date:  1983-04

6.  Serum hyaluronate reflects hepatic sinusoidal capillarization.

Authors:  T Ueno; S Inuzuka; T Torimura; S Tamaki; H Koh; M Kin; T Minetoma; Y Kimura; H Ohira; M Sata
Journal:  Gastroenterology       Date:  1993-08       Impact factor: 22.682

7.  Change in serum hyaluronan: a simple index of short-term drug-induced changes in hepatic sinusoidal perfusion.

Authors:  P R Gibson; J R Fraser; J C Colman; P A Jones; G Jennings; F J Dudley
Journal:  Gastroenterology       Date:  1993-08       Impact factor: 22.682

8.  Immunohistochemical study of hepatic fibrosis induced in rats by multiple galactosamine injections.

Authors:  A M Jonker; F W Dijkhuis; M J Hardonk; P Moerkerk; J Ten Kate; J Grond
Journal:  Hepatology       Date:  1994-03       Impact factor: 17.425

9.  Serum hyaluronate in liver diseases: study by enzymoimmunological assay.

Authors:  T Frébourg; B Delpech; E Bercoff; J Senant; P Bertrand; Y Deugnier; J Bourreille
Journal:  Hepatology       Date:  1986 May-Jun       Impact factor: 17.425

10.  Clinical significance of human hepatocyte growth factor in blood from patients with fulminant hepatic failure.

Authors:  H Tsubouchi; S Hirono; E Gohda; H Nakayama; K Takahashi; O Sakiyama; H Miyazaki; J Sugihara; E Tomita; Y Muto
Journal:  Hepatology       Date:  1989-06       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.